Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

British Journal of Cancer

Volumn 111, Issue 4, 2014, Pages 646-650

  D'Incalci, M ^a   Badri, N ^b   Galmarini, C M ^b   Allavena, P ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PHARMAMAR S A   (Spain)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

macrophages; microenvironment; sarcoma; trabectedin

Indexed keywords

DOXORUBICIN; PLATINUM; TRABECTEDIN;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER PATIENT; CANCER RECURRENCE; DRUG MECHANISM; HUMAN; METASTASIS INHIBITION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; HUMANS; LIPOSARCOMA, MYXOID; TETRAHYDROISOQUINOLINES; TRANSLOCATION, GENETIC; TUMOR MICROENVIRONMENT;

EID: 84906092874     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.149     Document Type: Review

References (45)

1. Allavena P, Mantovani A (2012) Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 167: 195-205.
2. Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, Olimpio CO, Bonardi C, Garbi A, Lissoni A, de Braud F, Jimeno J, D'Incalci M (2005) Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 65: 2964-2971.
3. Aune GJ, Takagi K, Sordet O, Guirouilh-Barbat J, Antony S, Bohr VA, Pommier Y (2008) Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin. Clin Cancer Res 14: 6449-6455.
4. Bissell MJ, Hines WC (2011) Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17: 320-329.
5. Bueren-Calabuig JA, Giraudon C, Galmarini CM, Egly JM, Gago F (2011) Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations. Nucleic Acids Res 39: 8248-8257.
6. Callata H, Manzano A, Sanchiz B, Alonso T, Gajate P, Sotelo M, Cabezas S, Aguado C, Diaz-Rubio E, Casado A (2013) Treatment with trabectedin enables retreatment with platinum-based chemotherapy in platinum-resistant and refractory (PRR) and partially platinum-sensitive (PPS) recurrent ovarian cancer (ROC) patients. ESGO 18th International Meeting: Liverpool, UK; 144.
7. Cuevas C, Francesch A (2009) Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep 26: 322-337.
8. Charytonowicz E, Terry M, Coakley K, Telis L, Remotti F, Cordon-Cardo C, Taub RN, Matushansky I (2012) PPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest 122: 886-898.
9. D'Incalci M, Galmarini CM (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9: 2157-2163.
10. D'Incalci M, Galmarini CM, de la Riba Alvarez I, Badri N, Schoffski P (2012) Association between body weight and efficacy outcomes during trabectedin therapy for recurrent advanced soft tissue sarcoma (STS). J Clin Oncol 30(suppl): abstr 10047.
11. Damia G, D'Incalci M (2007) Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 43: 1791-1801.
12. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M (2001) Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92: 583-588.
13. Del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, Gore M, Zintl P, Gomez J, Parekh T, Park YC, McMeekin S (2013) Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol 30: 435.
14. Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, Gronchi A, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JM, D'Incalci M (2013) Mode of action of trabectedin in myxoid liposarcomas. Oncogene; e-pub ahead of print 11 November 2013; doi:10.1038/onc.2013.462.
15. Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D'Incalci M (2001) Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37: 97-105.
16. Ferrandina G, Salutari V, Vincenzi B, Marinaccio M, Naglieri E, Loizzi V, Carpano S, Amadio G, Tonini G, Scambia G, Lorusso D (2013) Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study. Gynecol Oncol 130: 505-510.
17. Feuerhahn S, Giraudon C, Martinez-Diez M, Bueren-Calabuig JA, Galmarini CM, Gago F, Egly JM (2011) XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids. Chem Biol 18: 988-999.
18. Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D'Incalci M, Pilotti S, Mantovani R (2009) Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 8: 449-457.
19. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW (2002) Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 62: 3377-3381.
20. Gago F, Hurley LH (2002) Devising a structural basis for the potent cytotoxic effects of ecteinascidin 743. In: Small Molecule DNA and RNA Binders: From Synthesis to Nuclear Acid Complexes, Demeunynck M, Bailly C, Wilson WD (eds) pp 643-675. Wiley-VCH: Weinheim, Germany.
21. Galmarini CM, D'Incalci M, Allavena P (2014) Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment. Mar Drugs 12: 719-733.
22. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P (2013) Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23: 249-262.
23. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P (2010) Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 70: 2235-2244.
24. Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ (2011) Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 13: 145-153.
25. Grohar PJ, Helman LJ (2013) Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol Ther 137: 216-224.
26. Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ (2013) Dual targeting of EWS-FLI1 activity and the associated DNA damage response with Trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res 20(5): 1190-1203.
27. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8: 595-602.
28. Grosso F, Sanfilippo R, Virdis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Pilotti S, Casali PG (2009) Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 20: 1439-1444.
29. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S (2006) Crosstalk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 66: 8155-8162.
30. Hollebecque A, Adenis A, Taieb S, Lebedinsky C, Penel N (2010) Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. Invest New Drugs 28: 529-530.
31. Hurley LH, Zewail-Foote M (2001) The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability. Adv Exp Med Biol 500: 289-299.
32. Jin S, Gorfajn B, Faircloth G, Scotto KW (2000) Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 97: 6775-6779.
33. Le Cesne A (2013) 13 years of trabectedin, 5 years of Yondelis(R): what have we learnt? Expert Rev Anticancer Ther 13: 11-19.
34. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
35. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 97: 6780-6784.
36. Monk BJ, Blessing JA, Street DG, Muller CY, Burke JJ, Hensley ML (2012) A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol 124: 48-52.
37. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78.
38. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
39. Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, Garcia-Fernandez LF, Cuevas C, Allavena P, Erba E, D'Incalci M (2013) Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis(R) (PM00104). Int J Cancer 133: 2024-2033.
40. Sanfilippo R, Casali PG (2013) The intriguing patterns of tumor response to trabectedin. Expert Rev Anticancer Ther 13: 21-24.
41. Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, Dei Tos AP, Raspagliesi F, Judson I, Casali PG (2011) Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol 123: 553-556.
42. Schoffski P, Taron M, Jimeno J, Grosso F, Sanfilipio R, Casali PG, Cesne AL, Jones RL, Blay JY, Poveda A, Maki RG, Nieto A, Tercero JC, Rosell R (2011) Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study. Eur J Cancer 47: 1006-1012.
43. Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JA, Larsen AK (2007) Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 104: 13062-13067.
44. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y (2001) Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7: 961-966.
45. Tavecchio M, Simone M, Erba E, Chiolo I, Liberi G, Foiani M, D'Incalci M, Damia G (2008) Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 44: 609-618.